ESLA (Estrella Immunopharma, Inc.) Stock Financials & Earnings | Market Cap Arena

ESLA (Estrella Immunopharma, Inc.) Stock Financials & Earnings | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

Mkt Cap$53M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$14M

EPS (TTM)-$0.37

Free Cash Flow (TTM)-$3M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$3M
Q1 23	$0	$0	-$150K
Q2 23	$0	$0	-$169K
Q3 23	$0	$0	-$2M
Q4 23	$0	$0	-$1M
Q1 24	$0	$0	-$470K
Q2 24	$0	$0	-$4M
Q3 24	$0	$0	-$3M
Q4 24	$0	$0	-$1M
Q1 25	$0	$0	-$2M
Q2 25	$0	$0	-$6M
Q3 25	$0	$0	-$5M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$108K	-$108K
Q1 23	-$276K	-$276K
Q2 23	-$213K	-$213K
Q3 23	-$275K	-$275K
Q4 23	-$11M	-$11M
Q1 24	-$4M	-$4M
Q2 24	-$292K	-$292K
Q3 24	-$2M	-$2M
Q4 24	-$896K	-$896K
Q1 25	-$466K	-$466K
Q2 25	-$415K	-$415K
Q3 25	-$727K	-$727K

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$3
Q3 24	$0
Q4 24	$4
Q1 25	$0
Q2 25	$0
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+2502.9%
Q1 23	—	-11.1%
Q2 23	—	-84.2%
Q3 23	—	+240.6%
Q4 23	—	-63.0%
Q1 24	—	+213.8%
Q2 24	—	+2233.6%
Q3 24	—	+80.5%
Q4 24	—	+2.9%
Q1 25	—	+348.2%
Q2 25	—	+40.4%
Q3 25	—	+42.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$102K	—
Q1 23	$102K	—
Q2 23	$0	—
Q3 23	$1M	—
Q4 23	$0	—
Q1 24	$0	—
Q2 24	$0	—
Q3 24	$0	—
Q4 24	$0	—
Q1 25	$159K	—
Q2 25	$159K	—
Q3 25	$152K	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$3M	$148K	—	—
Q1 23	$3M	$118K	$19K	—
Q2 23	—	—	—	$155K
Q3 23	$483K	$1M	—	—
Q4 23	$75K	$945K	—	—
Q1 24	$25K	$445K	—	—
Q2 24	$4M	$424K	—	—
Q3 24	$3M	$551K	—	—
Q4 24	$33K	—	—	$1M
Q1 25	$1M	$694K	—	—
Q2 25	$5M	$884K	—	—
Q3 25	$4M	$649K	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$3M	$0	$3M
Q1 23	$29K	$0	$29K
Q2 23	$35K	$0	$35K
Q3 23	$22M	$0	$22M
Q4 23	$9M	$0	$9M
Q1 24	$5M	$0	$5M
Q2 24	$4M	$0	$4M
Q3 24	$2M	$0	$2M
Q4 24	$917K	$0	$917K
Q1 25	$421K	$0	$421K
Q2 25	$1M	$0	$1M
Q3 25	$2M	$0	$2M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	2M	-60.2%
Q1 23	2M	+0.0%
Q2 23	2M	+0.0%
Q3 23	1M	-54.8%
Q4 23	35M	+3244.0%
Q1 24	36M	+0.9%
Q2 24	37M	+3.1%
Q3 24	36M	-1.1%
Q4 24	37M	+1.3%
Q1 25	36M	-1.3%
Q2 25	36M	-0.1%
Q3 25	37M	+2.6%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 20	—	—
FY 21	—	—
FY 22	—	—
FY 23	$0	1
FY 24	$0	1